AstraZeneca to Acquire Alexion: Greater Scientific Presence In Immunology by Adding Alexion’s Innovative Complement-technology Platforms and Strong Pipeline

December 12, 2020 AstraZeneca announced today they have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based […]